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Abstract: 
Atrial fibrillation (AF) is the most common sustained arrhythmia in the general 
population. As an age-related arrhythmia AF is becoming a huge socio-economic 
burden for European healthcare systems. Despite significant progress in our 
understanding of the pathophysiology of AF therapeutic strategies for AF have not 
changed substantially and the major challenges in the management of AF are still 
unmet. This lack of progress may be related to the multifactorial pathogenesis of atrial 
remodeling and AF that hampers the identification of causative pathophysiological 
alterations in individual patients. Also, again new mechanisms have been identified 
and the relative contribution of these mechanisms still has to be established. In 
November 2010, the European Union launched the large collaborative project 
EUTRAF (=European Network of Translational Research in Atrial Fibrillation) to 
address these challenges. 
The main aims of EUTRAF are to study the main mechanisms of initiation and 
perpetuation of AF, to identify the molecular alterations underlying atrial remodeling, 
to develop markers allowing to monitor this processes and suggest strategies to treat 
AF based on insights in newly defined disease mechanisms. This article reports on the 
objectives, the structure and initial results of this network. 
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Condensed abstract:  
The FP7 large scale collaborative project EUTRAF has developed into the main 
research platform for translational research in AF in Europe. In a unique 
multidisciplinary and translational approach new concepts of genetic mechanisms, 
molecular pathophysiology and electro-imaging techniques are implemented in the 
development of new diagnostic tools for AF and new methods of catheter ablation. 
Numerous preclinical concepts developed in EUTRAF are currently tested in clinical 
trials or have resulted in new research network initiatives. The ultimate objective of 
EUTRAF is to pave the way for a new mechanistic classification enabling a 
personalized approach in AF.  
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1. Current challenges in AF management and resulting research questions 
The increase in life expectancy and recent improvements in treatment of acute heart 
disease have resulted in a major increase in the number of patients suffering from 
heart failure and atrial fibrillation (AF). AF is most the common sustained arrhythmia 
in the population occurring in 1 to 2% of the general population. More than 6 million 
Europeans suffer from this arrhythmia and in an ageing society this number is 
expected to rise quickly. AF is associated with an increased risk of stroke, dementia, 
heart failure and death (1,2). In Europe, one percent or even more of the health care 
budget is spent on AF management (3). Although the socio-economic burden of AF is 
growing steadily and significant progress has been made in understanding the 
pathophysiology of this arrhythmia, treatment of AF patients is still far from 
satisfactory. Anti-arrhythmic drugs, although reasonably effective for acute 
termination of AF, are unable to prevent recurrences of AF. Prevention of 
thromboembolic events requires anticoagulation therapy with all the associated risks. 
Radio-frequency ablation, originally developed for treatment of paroxysmal AF, is 
not as effective in persistent AF and is associated with potentially serious procedural 
risks (4).  
The authors believe that the relative slow progress in the development of 
antiarrhythmic, ablation and upstream AF therapies over the past years largely reflects 
our inability to identify the leading molecular mechanisms of the atrial remodeling 
process and the occurrence of AF in an individual patient.  
The central objective of the large collaborative project EUTRAF (European Network 
for Translational Research in Atrial Fibrillation) is (1) to identify these main 
molecular mechanisms of AF progression, (2) to develop serum, imaging and 
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electrophysiological markers allowing to monitor these processes and (3) develop 
strategies to treat AF based on insights in these disease mechanisms.  
 
2. Mission statement of EUTRAF 
The “European Network for Translational Research in Atrial Fibrillation” (EUTRAF) 
is a framework programme 7 large collaborative project supported by the European 
Union. 
EUTRAF’s general mission is to improve the management of AF in Europe. To 
achieve this, methods for identification of patients who are at-risk for AF at an early 
stage need to be developed and a better understanding of the factors leading towards 
persistent AF need to be obtained. Also, accurate diagnostic tools for identification of 
disease mechanisms in an individual patient and new therapies for each patient based 
on these individual disease mechanisms have to be defined.  
More specifically EUTRAF will 
- provide a multidisciplinary understanding of the diverse pathophysiological 
mechanisms of AF on the molecular, cellular, tissue and organ level. 
- integrate this knowledge into understanding of the electrophysiological mechanisms 
initiating and perpetuating AF. 
- identify and validate markers for the main molecular mechanisms of AF that can be 
used in patients. 
- propose a classification of AF that integrates major disease mechanisms and the 
electrophysiological characteristics of the fibrillating atria. 
- develop new therapeutic strategies targeting individual disease mechanisms. 
- disseminate the knowledge about new diagnostic tools and therapeutic techniques in 
the public domain. 
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3. Participants and structure of EUTRAF 
EUTRAF is a multidisciplinary consortium of expert groups involved in AF research. 
It was granted an amount of 12 million €. The total project budget is 16 million €. The 
programme was launched in November 2010. The active funding period will end by 
the end of October 2015 but the research initiated and developed by EUTRAF 
partners will continue for many more years.    
The consortium consists of academic research groups and industry partners. Expertise 
ranges from molecular biology, genetics and experimental electrophysiology, to 
engineering, computer science and cardiology. EUTRAF partners work in a matrix 
structure organized around central work packages each of which will utilize the full 
range of expertise provided by the network.  
The consortium is led by Professor John Camm from St. George‘s University of 
London (UK). Table 1 gives the list of the academic and industrial partners. These 
partners will define the main biological mechanisms that lead to the slow but 
progressive process of atrial remodeling increasing the propensity to AF. This atrial 
disease together with the molecular remodeling occurring as a consequence of AF 
determine the progression of AF from paroxysmal to persistent forms of the 
arrhythmia.  
Figure 1 shows the organizational structure of EUTRAF. The basic research 
undertaken to define the genetic, molecular, cellular and structural mechanisms of 
atrial remodeling are investigated in 5 basic research work packages (WPs). Apart 
from new insights into the mechanisms of AF these WPs deliver new biomarkers and 
new therapeutic targets for AF. These suggestions are explored in two clinical work 
packages, one of which focuses on new diagnostic tools for AF classification while in 
others new therapeutic approaches are investigated. Data analysis and integration is 
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accommodated in an eighth work package, which at the same time serves as IT 
platform. The consortium has access to several data sets of large clinical trials that are 
used for marker validation (e.g. Flec-SL, EAST-Trial, Anti-PAF, Maastricht-Study) 
(5-8). The ideas developed by EUTRAF partners have also led to the initiation of new 
clinical investigations as add-on studies on existing trials, new cohorts or new 
interventional trials.   
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4. Main research objectives and recent achievements  
 
This section describes per work package (WP) examples of research projects 
undertaken by EUTRAF partners in attempt to unravel new mechanisms of AF, to 
relate them to clinical signs and symptoms, to develop new diagnostic tools for AF 
und to improve current therapeutics strategies. 
 
4.1. WP1: Extracellular matrix and structure-function relationship  
WP1 addresses questions related to the structural determinants of conduction 
disturbances in atrial muscle. Adverse heterocellular crosstalk between cardiac 
stromal and parenchymal cells at the structural, mechanical, humoral and electrotonic 
level are likely to contribute to arrhythmogenesis in fibrotic hearts. Among the 
different modalities of stroma-parenchyme interactions, it was found that mechanical 
strain acting on myofibroblasts that are electrotonically coupled to myocytes causes 
substantial slowing of impulse conduction because of activation of stretch sensitive 
channels in myofibroblasts resulting in a secondary depolarization of coupled 
myocytes (9). With respect to humoral interactions, it was found that the main growth 
factor involved in cardiac fibrotic tissue remodeling, transforming growth factor-β1 
(TGF-β1), substantially aggravates the arrhythmogenic effect of myofibroblasts on 
electrotonically coupled myocytes. While TGF-β1 had little effect on conduction in 
myocyte preparations, it caused significant conduction slowing and increased ectopic 
activity in a fibrosis model (figure 2). Together, the findings suggest that 
arrhythmogenesis in fibrotic hearts in the context of mechanical stress and humoral 
factors may be dependent on myofibroblasts acting as primary ‘sensors’ that signal to 
adjacent myocytes through gap junctional coupling.  
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Fibroblasts and myofibroblasts can not only crosstalk to atrial myocytes but also to 
adipocytes located in the epicardial adipose tissue or infiltrating the myocardium. 
This cell type is an important source of adipokines that can diffuse freely in the 
neighboring atrial myocardium. EUTRAF partners found that human epicardial 
adipose tissue secretes activin A, a member of the TGF-β family, that has a marked 
fibrotic effect on the atrial myocardium by stimulating myofibroblasts. EUTRAF 
partner currently investigate which clinical conditions are associated with an 
abnormal biological activity of epicardial adipose tissue and how this activity could 
contribute to the formation of the AF substrate (10).  
 
4.2. WP2: Ion channel remodeling and Ca2+ handling 
Primary objective of WP2 is the characterization of molecular indicators 
(‘biomarkers’) and regulators of abnormal function of ion channels in the context of 
AF. For example, EUTRAF partners could show that shear stress increases membrane 
availability of the Kv1.5-subunit underlying the ultrarapid delayed rectifier current 
(IKur) from subcellular pools through an integrin-dependent pathway, thereby 
shortening atrial action potential duration (11). This highlights that not only the shape 
of the action potential (12) but also the spatial distribution of ion channel pore units 
play an important role in AF-related ion-current remodeling. There is also 
accumulating evidence for altered intracellular Na+-handling and downstream Na+-
dependent ion-channel regulation in AF. EUTRAF partners demonstrated that both 
IK1 and IK,ACh are regulated by intracellular Na
+ in human atrial myocytes of SR 
patients, whereas Na+-dependent regulation of IK,ACh was lost in chronic AF patients 
(13). Recent EUTRAF studies have identified Ca2+-handling abnormalities leading to 
delayed afterdepolarizations in AF patients (Ca2+ handling instability) (14,15). On the 
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other hand, sustained tachycardia and AF as such have also been demonstrated to 
induce a pattern of changes which reduce the likelihood of Ca2+ related proarrhythmic 
cellular events (Ca2+ signaling silencing) (16). It is currently unclear whether Ca2+ 
instability or Ca2+ handling silencing prevails in patients with AF.  
 
4.3. WP3: Etiological diversity of AF 
Many patients with clinical AF suffer from underlying heart disease. Hypertension, 
heart failure, diabetes and ageing are all strong predictors of AF. Accumulation of 
clinical factors increases the individual risk of developing AF by adding to AF 
complexity, presumably via diverse pathophysiological processes related to the 
underlying conditions.  
EUTRAF partners have invested considerable efforts in the development of risk 
factor-based AF models to systematically identify disease-specific mechanisms of AF. 
The ultimate aim is to identify substrate-specific biomarkers related to the pathology 
and stage of the underlying disease to optimize early diagnosis and therapeutic 
strategies. Established animal models include rat models with genetic hypertension or 
diabetes. These models are particularly suitable for long-term studies addressing the 
underlying mechanisms and complex interactions between ageing and disease-
specific progression of AF. For instance, atrial myocytes from hypertensive rats with 
early compensated LV hypertrophy showed distinct alterations in subcellular calcium 
handling consisting of reduced (-20%) L-type Ca2+ current, reduced (-55%) Na+/Ca2+ 
exchanger current and reduced (-33%) fractional SR Ca2+ release at increased SR Ca2+ 
load (17).  
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Very few animal studies address the interaction between AF-induced remodeling and 
disease-specific remodeling during the development of the AF substrate. For this 
reason, we have established a pig model that combines rapid pacing with hypertension.  
The combined model developed a much more severe phenotype in terms of atrial 
dilatation compared to ´lone` AF. This was associated with faster onset and 
progression of sustained AF. 80% of hypertensive pigs had developed sustained AF 
(>1h) after 2 weeks of rapid pacing as compared to 20% of pigs without underlying 
hypertension. This model will prove useful for the identification of specific signaling 
pathways involved in hypertension-induced structural remodeling stabilizing and for 
testing the efficacy of new antiarrhythmic drugs in the setting of hypertension. 
 
4.4. WP4: Atrial metabolic and redox alterations in AF 
In WP4 atrial metabolic and redox alteration are investigated as they may provide so 
far unexplored targets for upstream therapy of AF. A relevant target for such 
treatment strategies is the nitric oxide-redox imbalance in the fibrillating atrial 
myocardium. EUTRAF partners showed that the mechanisms responsible for this 
imbalance change with the duration of AF. In the first weeks of AF, activity and 
expression of NOX2 are upregulated in the left atrial myocardium. However, in later 
stages (months of AF), the oxidase systems underlying the increase in reactive oxygen 
species in both atria shift from NOX2 to mitochondrial oxidases and uncoupled nitric 
oxide synthases (18). Correspondingly, ex vivo incubation of atrial tissue with 
atorvastatin inhibits atrial Rac1 and NOX2 activity in right atrial samples from 
patients who develop AF after cardiac surgery, but does not affect atrial reactive 
oxygen species production and nitric oxide synthase activity in a patients with 
permanent AF (19). This implies that NOX2 inhibition by drugs such as statins may 
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be only effective in preventing new-onset AF or early AF-induced electric remodeling 
of the atrial myocardium. Indeed, in patients undergoing cardiac surgery, atrial 
superoxide and peroxynitrite levels were independently associated with an increased 
risk of post-operative AF and preoperative atorvastatin treatment for 3 days was 
sufficient to lower atrial NOX2 activity and superoxide level before changes in LDL 
cholesterol developed. 
Another related factor is the balance between atrial energy/ oxygen demand and 
supply. Little is known about how atrial oxygen supply responds to increased demand, 
and under which conditions it falls short (supply-demand mismatch). We have 
recently reported that in normal healthy pigs the left atrium has a lower coronary flow 
reserve than the left ventricle, but a higher oxygen extraction reserve (20). Although 
both reserves were recruited during short-term AF, a supply-demand mismatch, as 
evidenced by increased lactate production, still arose in the left atrium. This 
imbalance may form a pivotal trigger that induces atrial structural changes on the 
longer term, and may therefore represent another interesting target for upstream 
therapy. 
 
4.5. WP5: Genetic causes of AF 
Atrial fibrillation shows familial clustering, and common genetic variants on 
chromosome 4q25 (and others) are associated with AF. To further understand the 
mechanisms conveying AF in patients with genetic variations, a mutation that 
increases the late sodium current was studied and the effects of increased expression 
of CREM in a mouse model of spontaneous AF were characterized. Also, the 
functional and gene expression effects of reducing pitx2, the gene that is closest to the 
genetic variants on chromosome 4q25, were investigated.  
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Patients with long QT syndrome develop short-lasting atrial arrhythmias triggered by 
“atrial afterdepolarizations” (21). Using a unique genetic model expressing a knock-in 
mutation of the cardiac sodium channel with an exclusive increase in late sodium 
current (D-KPQ-SCN5A knockin) it was demonstrated that prolongation of the atrial 
action potential, early afterdepolarizations and pause-dependent atrial arrhythmias 
explain this monogenic form of AF (22).  
The myocyte-directed expression of the splice variant CREM-IbΔC-X of transcription 
factor CREM in mice (CREM-TG) led to spontaneous-onset AF associated with an 
increased CamKII mediated phosphorylation of RyR2 (21,22). EUTRAF partners 
described an arrhythmogenic substrate preceding AF in CREM-TG mice 
characterized by distension of atria with disorganized and elongated cardiomyocytes 
(23). The atrial remodeling represents a key event in the development of AF in this 
model that precedes the occurrence of AF and is associated with atrial ectopics and 
triggering of AF episodes by programmed stimulation in young transgenic mice. 
Functional changes in CREM-TG atria are related to the electrophysiological 
properties of atrial myocytes and further alterations suggesting that Ca2+-dependent 
mechanisms also contribute to the development of AF.  
Pitx2 expression was also studied as a marker for “leftness” in the atria. EUTRAF 
partners could demonstrate that pitx2, a paired homeobox transcription factor that is 
implicated in left-right differentiation during embryonic development, is expressed at 
relatively high levels in the adult left, but not right, atrium (24). It was demonstrated 
that reduced pitx2 expression shortens the atrial action potential, especially at short 
pacing cycle lengths, and predisposes to atrial fibrillation in the absence of gross 
structural atrial abnormalities (24). EUTRAF partners are currently trying to identify 
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whether these genes could be relevant as functional mediators conveying AF and/or 
as biomarkers to identify patients with “polygenic AF” (25). 
 
4.6. WP6: Classification of AF with new diagnostic tools 
WP6 of EUTRAF aims at developing non-invasive tools that may provide 
information on the relative degree of electrophysiological changes in the atria. The 
slow but steady process of structural remodeling in the atria (26-28) could possibly 
monitored by advanced analysis of surface ECGs (29,30). 
Within the EUTRAF consortium a large software package allowing for quantification 
of multiple ECG parameters reflecting the complexity of the fibrillatory pattern 
during AF is developed. The analysis of AF ECGs in more than 500 AF patients using 
this software package revealed that a combination of different mathematical 
techniques (e.g. f-wave amplitude and organization index of the power spectrum) and 
multiple leads has a higher predictive value for outcome than a single method on 
single leads. Importantly, the ECG predictors had a comparable or higher predictive 
value than established clinical predictors like age, gender, LV-performance, heart 
dimensions, or co-morbidities. 
For example, in 132 patients undergoing stepwise catheter ablation the predictive 
value of ECG parameters for acute termination of AF (f-wave amplitude of aVR and 
dominant frequency of aVF, area under the receiver operator curve AUC = 0.75) was 
comparable to the performance of best clinical predictors (duration of the current AF 
episode plus LA diameter, AUC = 0.74) The combination of clinical with ECG 
predictors improved C-statistics to AUC=0.81. For long-term outcome, ECG 
parameters alone predicted long-term success of catheter ablation even better than 
clinical predictors (AUC 0.82 vs 0.68, respectively). 
16 
 
 
Because of the close anatomical relation between the esophagus and the left atrial 
posterior wall, a transesophageal ECG has been suggested as a technique to 
characterize LA electrophysiological properties. So far these studies were limited to a 
frequency analysis of the esophageal ECG (31). The EUTRAF consortium developed 
a technique to determine the complexity of AF in the posterior wall of the left atrium 
by fractionation analysis of the transesophageal ECG (TE-ECG). Figure 3 
demonstrates the excellent match between frequency and complexity of the atrial 
activation in the atrium (LA, gold standard) and the TE-ECG. This technique is 
currently being evaluated prospectively.  
In order to stimulate the process of standardization and harmonization of the 
assessment of AF complexity from surface ECG EUTRAF members hosted the first 
European Conference for Standardization of Advanced ECG Analysis in Arrhythmia 
Diagnostics focusing on Quantification of the Atrial Fibrillation Substrate Complexity, 
in Lugano, Switzerland, in December 2013. At this conference details on technical 
standards were discussed and common studies for correlating ECG parameters to AF 
mechanisms were initiated.  
 
4.7. WP7: Improving AF therapy by mechanism-based therapies 
Treating AF through surgical or catheter ablation is based on the elimination of the 
triggers initiating the arrhythmia and/or the substrate maintaining it. In paroxysmal 
AF, ablation successfully targets triggers, which are mainly located in the pulmonary 
veins (PVs). In persistent AF results are less satisfactory, presumably because of the 
influence of wider atrial substrate for AF perpetuation (32). For determining a 
therapeutic strategy in persistent AF (localized target vs. global intervention), the key 
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question is whether the activation waves that perpetuate persistent AF individually 
emanate from few, stable, and localized drivers or whether the waves are transitory, 
widely distributed and self perpetuating. Localized drivers are difficult to detect in 
persistent AF with conventional techniques because of limitations in technology for 
sequential mapping, high degree of electrograms fractionation, intermittent firing and 
spatial meandering of fibrillation waves.  
Recent developments have allowed biatrial AF mapping using activation or phase-
based analysis of body surface potentials. For this reason EUTRAF partners have 
studied the ability of non-invasive mapping to identify driver-domains and 
characterize them in persistent human AF. 
In 103 consecutive patients with persistent AF, accurate bi-atrial geometry relative to 
an array of 252-body-surface electrodes was obtained from non-contrast CT-scan (33). 
The reconstructed unipolar AF-electrograms were signal-processed to identify the 
drivers (focal or re-entrant activity) and their cumulative density-map was constructed 
(Figure 4). The driver domains were catheter ablated using AF termination as 
procedural endpoint in comparison with stepwise-ablation control group. The maps 
showed changing beat-to-beat wavefronts and varying spatio-temporal behaviour of 
driver activities. Re-entries were not sustained and meandered substantially but 
recurred repetitively. Their locations could be described not as discrete sites but as 
regions. Ablation of driver regions alone terminated 75% and 15% of persistent and 
long-lasting AF, respectively. The procedural times were approximately 2-times 
shorter as compared to the traditional step-wise approach. At 6 months after the 
ablation, 83% patients with AF-termination were free from AF, similar to control 
population undergoing step-wise AF ablation (84%,). Thus, the non-invasive system 
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can map AF before the procedure and help to shorten invasive procedural time. 
Further clinical evaluation is currently ongoing.  
 
4.8. WP8: Insights in AF mechanisms derived from information science and 
analysis of large scale data sets 
Analysis of large cohorts and databases offers the opportunity to validate markers 
identified in a hypothesis-driven approach but also find new associations by 
hypothesis-free strategies, for example by using data mining techniques. The first 
objective of large-scale data analysis is standardized and scalable data collection, for 
which a proper IT infrastructure including data warehouse was implemented in the 
EUTRAF project. An additional clustered data warehouse was built on-site for the 
TRAF (Turkish Atrial Fibrillation Database) registry in the Social Security Institution 
of Turkey based on the Microsoft SQL Server Enterprise 2013 database, on which the 
associated Analysis Services module was run for data analysis. The required security 
and privacy mechanisms for all the above-mentioned tools have been developed and 
implemented to provide confidentiality of patient specific information and to address 
ethical issues based on EU directives. 
The objective of these analyses is to discover mechanistic relationships between 
biomarkers and the development and perpetuation of AF, to assess the predictive 
value of existing biomarkers, and to reveal new valuable biomarkers as well as new 
therapeutic targets. Through collaborations with 5 different groups in the EUTRAF 
consortium as well as the German Network of Excellence for Atrial Fibrillation (AF-
NET), the Flec-SL and ANTIPAF clinical datasets as well as datasets collected by the 
University of Dresden (APDRS) and Maastricht University are analyzed. Finally, 
with the collaboration of MITS, St. George’s University London, and the University 
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of Leeds, the largest national cohort of AF patients worldwide, the TRAF (Turkish 
Registry in Atrial Fibrillation) database has been built.  
For example, the re-analysis of the Flec-SL cohort (6) through machine learning 
techniques has revealed that successful pharmacological conversion prior to the 
beginning of the survey period had the greatest effect in predicting whether a patient 
would reach the primary endpoint (conversion to persistent AF or mortality). The 
TRAF database contains the records of 545,000 patients who had the diagnosis of 
non-valvular AF within the years 2008-2012. TRAF is extracted from a claims and 
utilization management system called MEDULA which processes claims for all 
health insurance funds in Turkey since 2007. Analysis of the TRAF database has for 
example revealed that warfarin significantly increases the rates of hospitalization, and 
mortality in the low risk groups (CHA2DS2VASc<2) and decreases hospitalization 
and mortality in high risk groups (CHA2DS2VASc>=2).  
All of these studies will merge and culminate with the development of a data-mining 
based model and pertaining clinical decision support system (CDSS) to assess the risk 
of AF and its complications, which is the final innovative and scientific objective of 
the work package.  
 
5. Outlook 
The authors believe that the scientific achievements of the EUTRAF consortium was 
and will be tremendously helpful for developing better understanding of the general 
pathophysiology of AF. Hopefully, this understanding will facilitate the development 
of future therapeutic strategies, such as ion channel blockers, upstream therapy, or 
ablation of AF. Some of these concepts are currently tested in clinical trials (table 2). 
While potentially proving useful in clinical practise, these concepts evolved along the 
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traditional flow of explorative clinical or experimental evaluation, integration in 
general understanding of pathophysiology, identification of a therapeutic target and 
validation in clinical trials (figure 5A).  
For the future, we foresee a shift in this strategy towards emphasis on individual 
disease mechanisms. We acknowledge that individual components of 
pathophysiological processes leading to AF, although assessable by experimental 
research, as yet have hardly had an impact on the choice of the therapeutic option. 
Experimental research within EUTRAF but also in many other projects has shown 
that inflammation, fibrosis, reactive oxygen species activation, or fatty infiltration can 
all contribute to the development and perpetuation of AF. However, these 
considerations are usually not taken into account in the choice for an individual 
therapy. The reasons are manifold and include the presence of multiple mechanisms 
and temporal variability of pathomechanisms in an individual patient. Also the 
individual genetic background, with the exception of monogenetic cardiac diseases, is 
usually not considered in the decision on a therapeutic strategy. To overcome this 
‘translational gap’ is one of the most important challenges in the development of a 
strategy for personalized AF therapy. A potential approach to this is shown on figure 
5B.  
The authors assume that in order to identify the main mechanisms responsible for 
atrial remodeling and AF and in order to determine the relative contribution of the 
different disease mechanisms a combined histological, biochemical and complex 
genetics approach is required. In this scenario it is essential that blood samples and 
atrial tissue is available in order to detect the molecular mechanisms leading to AF. At 
the same time, detailed clinical characterization of the patients is required so that the 
molecular mechanisms can be correlated to clinical signs and symptoms.  
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From blood samples, common gene variants (SNPs) and a list of predefined 
biomarkers would need to be determined. Histological investigation of the tissue will 
show degree and distribution of fibrosis, amyloidosis, fatty infiltration, vascular 
rarefaction, inflammation and other mechanisms. Biochemical studies will reveal 
ROS production, ion channel alterations, and activity of prohypertrophic, profibrotic, 
and proinflammatory pathways (e.g. RAS, TGF-β1). Gene-expression profiling could 
be used to identify differentially expressed genes informing on statistically enriched 
signaling pathways. The information from all these investigations will allow for 
identification of the ‘leading molecular mechanisms’ in a specific patient. Preferably, 
the mechanisms should be identified on the tissue or biochemical pathway level. In a 
second step, a mathematical model to detect the leading molecular mechanisms from 
parameters measured in blood samples, ECGs, echocardiography, and clinical profile 
could be constructed. From blood samples, ECGs, echocardiography, and clinical 
profile information of the same patients (the patients from whom atrial tissue was 
obtained) a large number of  ‘features’ would be determined in each patient. A feature 
can be, for example, gender, age, LA size, comorbidity, a common gene variant, 
elevation of a biomarker, upregulation of a miRNA, an ECG parameter, or a 
medication. From all this information a model is constructed that assigns a patient to 
the correct leading molecular mechanisms based on a selection of features. At the end 
of this step, it is possible to read out the leading molecular mechanisms from a 
(hopefully) limited list of parameters that can be determined from blood, ECGs, 
echocardiography, or clinical profile of the patients. 
The ultimate goal of this approach is to develop a classification of AF which is based 
on clinical symptoms and signs and a hopefully short list of biomarkers but which 
informs on leading pathophysiological mechanism of AF in a specific patient 
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allowing for therapy tailored to these mechanisms. This shift in approach would mean 
to replace clustering patients in larger groups assumed to have developed comparable 
disease mechanisms by detecting their individual disease mechanisms. Instead 
treating them according to guidelines, decision support systems could help to identify 
the optimal therapy in an individual patient.  
Such strategies are more than a daydream. They have been implemented in 
personalized medicine strategies in various chronic diseases such as Alzheimer’s 
disease or some forms of cancer (34,35). Increasing restrictions in health care budgets 
call for reinforcement of personalized approaches also in cardiovascular diseases. 
Taking advantage of their broad and translational expertise EUTRAF partners are 
well positioned to deliver significant contributions to this process. 
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Table 1 
St-George’s University of London (UK) 
Maastricht University (The Netherlands) 
Université Pierre Marie Curie – Paris (France) 
Technische Universität Dresden (Germany) 
Centre Hospitalier Universitaire – Bordeaux (France) 
Westfälische Wilhelms-Universität Münster (Germany) 
University Hospital Magdeburg (Germany) 
Universität Bern (Switzerland) 
University Hospital Graz (Austria) 
Medical Information Technology Solutions (Turkey) 
University of Oxford (UK) 
UK Health & Environment Research Institute (UK) 
Sanofi-aventis Deutschland GmbH (Germany) 
Osypka AG (Germany) 
Xention Ltd (UK) 
Universität Duisburg-Essen – Essen (Germany) 
Philipps Universität – Marburg (Germany) 
Ernst-Moritz-Arndt Universität – Greifswald (Germany) 
 
Table 1: Institutions participating in EUTRAF 
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Table 2 
Study title / 
acronym 
Organizing 
partner site 
Number of 
patients  
Research objective 
MULTI-AF UM 220 Predictive value of new ECG and biomarkers in patients 
undergoing electrical cardioversion 
PROTON UM 40 Identification of rotors during AF by sinusoidal 
recomposition and Hilbert transform of endocardial 
electrograms in patients undergoing catheter ablation for 
AF 
MAPAC UM 150 Direct contact mapping of patients undergoing open chest 
surgery, correlation of conduction disturbances with 
tissue-, serum-, and ECG markers 
Late-POAF UM 100 Identification of tissue-, serum-, and ECG-markers for 
incident AF in SR patients undergoing open chest surgery.  
STICS Oxford 1922 Randomised, double-blind, placebo-controlled trial of the 
effect of perioperative rosuvastatin on postoperative AF 
and myocardial damage  
TRAF Ankara 545000 TRAF (Turkish Atrial Fibrillation Database) registry in the 
Social Security Institution of Turkey. 
Association between comorbidities, medication, and 
hospitalization with progression of AF and stroke. 
 
Table 2: Ongoing clinical studies testing scientific concepts developed by EUTRAF 
partners. 
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Figure Legends: 
 
Figure 1: Organizational structure of EUTRAF. The research topics are explained in 
more detail in section 4. 
 
Figure 2: Precipitation of sustained reentrant activity in models of fibrotic 
myocardium (myocyte monolayers coated with myofibroblasts). Spontaneously 
arising functional reentry (central disc, 800 µm diameter) is, in some preparations, 
accompanied by anatomical reentry (peripheral ring of tissue, separated by a gap from 
the central disc). The frequency of reentrant activity in the 6 preparations shown 
ranged from 3 to 8 Hz (voltage sensitive dye recordings). 
 
Figure 3: Excellent match between atrial activations (red A) in the left atrial posterior 
wall (upper tracing) and the TE-ECG (mid tracing). Please note, that the atrial 
deflections show a low complexity (low fractionation index) in both LA-electrograms 
as well as in the TE-ECG on the left and a high degree of fractionation (high number 
of small high frequency deflections) in the right part of the tracing. Such differences 
are not seen in the surface ECG.  
 
Figure 4: Vest carrying 252 electrodes placed on the patient’s chest (A) during CT 
scan (B) to reconstruct cardiac activation which is then analyzed with a phase 
mapping algorithm (C). A rotor is seen on that map (arrow). The rotors and foci are 
then displayed on cumulative maps (D) to identify the most active region and 
hierarchize the ablation. 
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Figure 5: Overcoming the translational gap between knowledge on mechanisms 
responsible for AF – often assessed by experimental research and the results of 
clinical investigations (A) forms an important challenge for the future. Detection of 
individual disease mechanisms by markers or parameters which can easily be 
measures in every patients and which at the same time inform on the relevant disease 
processes are required to close the translational gap and to develop an individualized 
therapeutic approach (B). 
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